Comorbidities in DLBCL: too "Severe4" CAR-T therapy?

Blood Adv. 2023 Jul 25;7(14):3469-3471. doi: 10.1182/bloodadvances.2023009834.
No abstract available

Publication types

  • Comment

MeSH terms

  • Comorbidity
  • Receptors, Chimeric Antigen*

Substances

  • Receptors, Chimeric Antigen